4.5 Article

Characterization of the Human Transcription Elongation Factor Rtf1: Evidence for Nonoverlapping Functions of Rtf1 and the Paf1 Complex

期刊

MOLECULAR AND CELLULAR BIOLOGY
卷 35, 期 20, 页码 3459-3470

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.00601-15

关键词

-

资金

  1. MEXT, Japan
  2. Grants-in-Aid for Scientific Research [23102002, 24118001] Funding Source: KAKEN

向作者/读者索取更多资源

Restores TBP function 1 (Rtf1) is generally considered to be a subunit of the Paf1 complex (PAF1C), a multifunctional protein complex involved in histone modification and transcriptional or posttranscriptional regulation. Rtf1, however, is not stably associated with the PAF1C in most species except Saccharomyces cerevisiae, and its biochemical functions are not well understood. Here, we show that human Rtf1 is a transcription elongation factor that may function independently of the PAF1C. Rtf1 requires Rtf1 coactivator activity, which is most likely unrelated to the PAF1C or DSIF, for transcriptional activation in vitro. A mutational study revealed that the Plus3 domain of human Rtf1 is critical for its coactivator-dependent function. Transcriptome sequencing (RNA-seq) and chromatin immunoprecipitation studies in HeLa cells showed that Rtf1 and the PAF1C play distinct roles in regulating the expression of a subset of genes. Moreover, contrary to the finding in S. cerevisiae, the PAF1C was apparently recruited to the genes examined in an Rtf1-independent manner. The present study establishes a role for human Rtf1 as a transcription elongation factor and highlights the similarities and differences between the S. cerevisiae and human Rtfl proteins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

The role of Mediator and Little Elongation Complex in transcription termination

Hidehisa Takahashi, Amol Ranjan, Shiyuan Chen, Hidefumi Suzuki, Mio Shibata, Tomonori Hirose, Hiroko Hirose, Kazunori Sasaki, Ryota Abe, Kai Chen, Yanfeng He, Ying Zhang, Ichigaku Takigawa, Tadasuke Tsukiyama, Masashi Watanabe, Satoshi Fujii, Midori Iida, Junichi Yamamoto, Yuki Yamaguchi, Yutaka Suzuki, Masaki Matsumoto, Keiichi Nakayama, Michael P. Washburn, Anita Saraf, Laurence Florens, Shigeo Sato, Chieri Tomomori-Sato, Ronald C. Conaway, Joan W. Conaway, Shigetsugu Hatakeyama

NATURE COMMUNICATIONS (2020)

Article Multidisciplinary Sciences

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide

Shumpei Tateno, Midori Iida, Satoshi Fujii, Tetsufumi Suwa, Miki Katayama, Haruka Tokuyama, Junichi Yamamoto, Takumi Ito, Satoshi Sakamoto, Hiroshi Handa, Yuki Yamaguchi

SCIENTIFIC REPORTS (2020)

Article Biochemistry & Molecular Biology

ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells

Junichi Yamamoto, Tetsufumi Suwa, Yuki Murase, Shumpei Tateno, Hirotaka Mizutome, Tomoko Asatsuma-Okumura, Nobuyuki Shimizu, Tsutomu Kishi, Shuji Momose, Masahiro Kizaki, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa

NATURE CHEMICAL BIOLOGY (2020)

Article Oncology

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Mitsuhito Hirano, Yoichi Imai, Yuta Kaito, Takahiko Murayama, Kota Sato, Tadao Ishida, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Tamami Denda, Yukihisa Tanaka, Yasunori Ota, Masanori Nojima, Yasuhiko Kamikubo, Noriko Gotoh, Shinsuke Iida, Hiroshi Handa, Arinobu Tojo

Summary: The study found that the combination of HDAC inhibitor and Akt inhibitor holds promise for the treatment of relapsed/refractory MM, as HDAC inhibitors suppressed drug-resistant MM cell growth and enhanced antibody-dependent cellular cytotoxicity, while also downregulating c-Myc through GSK-3 phosphorylation blockage.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Article Oncology

Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells

Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, Hideto Tamura

Summary: IMiDs induce PD-L1 expression on MM cells through the BCMA-APRIL pathway and Ikaros degradation mediated by CRBN. Combination therapy of durvalumab and IMiDs effectively reverses T-cell inhibition induced by PD-L1-upregulated cells.

MOLECULAR CANCER THERAPEUTICS (2021)

Article Biochemistry & Molecular Biology

Three human RNA polymerases interact with TFIIH via a common RPB6 subunit

Masahiko Okuda, Tetsufumi Suwa, Hidefumi Suzuki, Yuki Yamaguchi, Yoshifumi Nishimura

Summary: This study reveals that the shared N-terminal tail (NTT) of the common subunit RPB6 in all three eukaryotic RNA polymerases interacts with the PH domain (PH-D) of the p62 subunit of TFIIH, playing crucial roles in transcription and nucleotide excision repair.

NUCLEIC ACIDS RESEARCH (2022)

Article Biology

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates

Nobuyuki Shimizu, Tomoko Asatsuma-Okumura, Junichi Yamamoto, Yuki Yamaguchi, Hiroshi Handa, Takumi Ito

Summary: Pomalidomide and lenalidomide, derived from thalidomide, are immunomodulatory agents with different indications. Pomalidomide has been shown to induce degradation of PLZF-RAR α, leading to anti-proliferative effects in leukemic cells.

COMMUNICATIONS BIOLOGY (2021)

Article Multidisciplinary Sciences

The 3′ Pol II pausing at replication-dependent histone genes is regulated by Mediator through Cajal bodies' association with histone locus bodies

Hidefumi Suzuki, Ryota Abe, Miho Shimada, Tomonori Hirose, Hiroko Hirose, Keisuke Noguchi, Yoko Ike, Nanami Yasui, Kazuki Furugori, Yuki Yamaguchi, Atsushi Toyoda, Yutaka Suzuki, Tatsuro Yamamoto, Noriko Saitoh, Shigeo Sato, Chieri Tomomori-Sato, Ronald C. Conaway, Joan W. Conaway, Hidehisa Takahashi

Summary: This study demonstrates the importance of Mediator in the transcription termination of replication-dependent histone genes. Mediator plays a role in pausing RNA polymerase II at the transcript end sites of these genes by associating with Cajal bodies, thereby facilitating the subsequent 3'-end processing.

NATURE COMMUNICATIONS (2022)

Article Biochemistry & Molecular Biology

Integrator complex subunit 15 controls mRNA splicing and is critical for eye development

Noriyuki Azuma, Tadashi Yokoi, Taku Tanaka, Emiko Matsuzaka, Yuki Saida, Sachiko Nishina, Miho Terao, Shuji Takada, Maki Fukami, Kohji Okamura, Kayoko Maehara, Tokiwa Yamasaki, Jun Hirayama, Hiroshi Nishina, Hiroshi Handa, Yuki Yamaguchi

Summary: This study reports the molecular and genetic characterization of Integrator complex subunit 15 (INTS15). INTS15 is highly expressed in the eye and brain, and it interacts with the Integrator complex to support small nuclear RNA 3' end processing. Knockdown of INTS15 leads to missplicing of numerous genes and affects genes associated with eye and brain development.

HUMAN MOLECULAR GENETICS (2023)

Review Chemistry, Multidisciplinary

Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa

Summary: Progress in strategies aimed at breaking down therapeutic target proteins has led to a paradigm shift in drug discovery. Thalidomide and its derivatives are currently the only protein degraders used in clinical practice. Understanding of their molecular mechanism of action, specifically their direct target cereblon (CRBN), has advanced dramatically. This discovery has demonstrated the clinical value of thalidomide derivatives and has contributed to the rapid development of protein-degrading agents.

CHEMICAL SOCIETY REVIEWS (2022)

Review Biochemistry & Molecular Biology

Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology

Takumi Ito, Yuki Yamaguchi, Hiroshi Handa

Summary: CRBN, originally associated with intellectual disability, is now recognized as the primary target of thalidomide, promoting ubiquitination and proteasomal degradation of specific neosubstrates. Small-molecule drugs binding CRBN, known as molecular glue degraders, enhance the interaction between CRBN and its neosubstrates. CRBN-based PROTACs, heterobifunctional molecules hijacking CRBN to induce degradation of target proteins, show promise in drug development.

CELL CHEMICAL BIOLOGY (2021)

暂无数据